The first group had the longest median overall survival (96 months) in comparison with patients with IDH1 mutations and ATRX loss (51 months), while the shortest median overall survival was in glioma patients who did not harbor any of those signatures (13 months) [15]. This evidence concerns the gene IDH1 and central nervous system cancer.